STREPTOMYCIN
Mycobacterium Avium Complex Disease
National Jewish HealthSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Mycobacterium Avium Complex Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Clarithromycin National Jewish Health | Phase 2 | B |
ETHAMBUTOL National Jewish Health | Phase 2 | B |
THIOPARAMIZONE National Jewish Health | Phase 2 | B |
RIFALDAZINE National Jewish Health | Phase 2 | B |
Azithromycin National Institute of Allergy and Infectious Diseases (NIAID) | N/A | D |
Same molecule, other indications
STREPTOMYCIN is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →